<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04285398</url>
  </required_header>
  <id_info>
    <org_study_id>PHENOROD2</org_study_id>
    <nct_id>NCT04285398</nct_id>
  </id_info>
  <brief_title>Prospective Natural History Study of Retinitis Pigmentosa</brief_title>
  <acronym>PHENOROD2</acronym>
  <official_title>One-Year Natural History Study of Retinitis Pigmentosa Due to RHO, PDE6A or PDE6B Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SparingVision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SparingVision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is natural history study of rods and cones degenerations in patients with Retinitis
      Pigmentosa (RP) caused by pathogenic mutations in RHO, PDE6A or PDE6B gene mutations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open, longitudinal, ambispective, single center study to describe one-year disease
      progression in patients with retinitis pigmentosa due to mutation in genes with selective
      expression in rods: rhodopsin (RHO), phosphodiesterase 6A (PDE6A) or phosphodiesterase 6B
      (PDE6B).RHO,PDE6A or PDE6B mutation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 12, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spectral Domain Optical Coherence tomography (SD-OCT)</measure>
    <time_frame>1 year</time_frame>
    <description>Progression of disease over time as measured by SD-OCT (EZ length, ELM length, ONL thickness, macular volume).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fundus Autofluorescence (FAF)</measure>
    <time_frame>1 year</time_frame>
    <description>Progression of disease as measured by FAF (Hyperautofluorescent ring)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Progression of disease over time as measured by best corrected visual acuity (BCVA) (ETDRS, Snellen) and refraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field</measure>
    <time_frame>1 year</time_frame>
    <description>Progression of disease over time as measured by kinetic and static visual fields</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-field stimulus threshold (FST)</measure>
    <time_frame>1 year</time_frame>
    <description>Progression of disease over time as measured by FST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color vision</measure>
    <time_frame>1 year</time_frame>
    <description>15 Hue Desaturated Lanthony</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dark adaptometry (DA)</measure>
    <time_frame>1 year</time_frame>
    <description>Progression of disease over time as measured by DA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Study Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One year follow up of patients with ophthalmic examination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>One year follow-up of patients with ophthalmic examination and mobility testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Ophthalmic examination</intervention_name>
    <description>Visual Acuity, Visual Field, FST, Dark adaptometry, Color Vision testing, OCT and FAF.</description>
    <arm_group_label>Study Group 1</arm_group_label>
    <arm_group_label>Study Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mobility Test</intervention_name>
    <description>Functional test to evaluate mobility and postural condition of patients</description>
    <arm_group_label>Study Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RP with mutations affecting the RHO, PDE6A and PDE6B genes

          -  Visual acuity ≥ 20/200 for at least one eye

          -  Binocular Visual field diameter ≥ 5° as measured on the Goldmann III-4e isopter

        Exclusion Criteria:

          -  Patients with any other gene mutation known to be involved in RP

          -  Patients with other ocular disorder likely to impact the visual function

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saddek Mohand-Saïd, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHNO XV-XX Paris - CIC 1423</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence Allouche</last_name>
    <phone>+33143462060</phone>
    <email>info@sparingvision.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHNO XV-XX Paris - CIC 1423</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saddek Mohand-Saïd, M.D, Ph.D</last_name>
      <email>mohand@quinze-vingts.fr</email>
    </contact>
    <investigator>
      <last_name>Saddek Mohand-Saïd, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>José-Alain Sahel, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Audo, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 24, 2020</study_first_submitted>
  <study_first_submitted_qc>February 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2020</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RHO</keyword>
  <keyword>PDE6A</keyword>
  <keyword>PDE6B</keyword>
  <keyword>Pathogenic Mutation</keyword>
  <keyword>Prospective</keyword>
  <keyword>Natural History</keyword>
  <keyword>Retinal Disease</keyword>
  <keyword>Eye Disease</keyword>
  <keyword>Blindness</keyword>
  <keyword>Inherited Eye Disease</keyword>
  <keyword>Vision Disorder</keyword>
  <keyword>Inherited Retinal Disorder</keyword>
  <keyword>Rod-Cone Dystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

